Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma

Blood (2025) 146 (Supplement 1): 7483.

https://doi.org/10.1182/blood-2025-7483

Published: 2025

Journal Articles

The molecular landscape of Waldenström macroglobulinemia identified using whole genome sequencing

Blood (2025) 146 (Supplement 1): 1770.

https://doi.org/10.1182/blood-2025-1770

Published: 2025

Journal Articles

Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study

Blood (2025) 146 (Supplement 1): 7479.

https://doi.org/10.1182/blood-2025-7479

Published: 2025

Journal Articles

A phase 2 trial of iberdomide, carfilzomib, daratumumab and dexamethasone quadruplet therapy for relapsed/refractory multiple myeloma: The rekindle study

Blood (2025) 146 (Supplement 1): 251.

https://doi.org/10.1182/blood-2025-251

Published: 2025

Journal Articles

A phase 2 trial of abbreviated fixed-duration (Default 4 Cycles) linvoseltamab immuno-consolidation to deepen responses post newly diagnosed multiple myeloma combination therapy for minimal residual disease positivity (the IMMUNOPLANT Study)

Blood (2025) 146 (Supplement 1): 248.

https://doi.org/10.1182/blood-2025-248

Published: 2025

Journal Articles

On the cellular origins of multiple myeloma

Blood (2025) 146 (Supplement 1): 5694.

https://doi.org/10.1182/blood-2025-5694

Published: 2025

Journal Articles

Chromothripsis drives high-risk multiple myeloma by copy number abnormalities and rewiring the epigenome to activate oncogenic programs.

Enze Liu, Nathan Becker, Sreejeta Mondal, Attaya Suvannasankha, David Coffey, Benjamin Diamond, Abhishek Pandey, Kelvin Lee, Dickran Kazandjian, Rafat Abonour, Aneta Mikulasova, Gareth Morgan, Ola Landgren, Brian Walker

Blood (2025) 146 (Supplement 1): 5693.

https://doi.org/10.1182/blood-2025-5693

Published: 2025

Journal Articles

Subclonal genomic heterogeneity shapes immune crosstalk and clinical outcomes in multiple myeloma

Parvathi Sudha, Sylvia Robertson, Sihong Li, Sean McCabe, Kelvin Lee, Rafat Abonour, Brian Walker, Attaya Suvannasankha, Travis Johnson

Blood (2025) 146 (Supplement 1): 5732.

https://doi.org/10.1182/blood-2025-5732

Published: 2025

Journal Articles

High-dimensional profiling reveals predominant depletion of NK cell effector phenotypes in relapsed/refractory multiple myeloma patients treated with anti-CD38 therapy

Blood (2025) 146 (Supplement 1): 5720.

https://doi.org/10.1182/blood-2025-5720

Published: 2025

Journal Articles

Cyclin D1 beyond the cell cycle: A new role in t(11;14) multiple myeloma

Blood (2025) 146 (Supplement 1): 3939.

https://doi.org/10.1182/blood-2025-3939

Published: 2025

Journal Articles

Multiomic evidence of coordinated complex rearrangements, enhancer hijacking, and epigenomic signatures in the first whole-chromosome-phased myeloma genomes

Nathan Becker, Enze Liu, Zackary Sanborn, Attaya Suvannasankha, Kelvin Lee, Dickran Kazandjian, James Hoffman, Benjamin Diamond, Abhishek Pandey, Rafat Abonour, Ola Landgren, Lisa Munding, Aneta Mikulasova, Brian Walker

Blood (2025) 146 (Supplement 1): 3928.

https://doi.org/10.1182/blood-2025-3928

Published: 2025

Journal Articles

Whole genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myeloma

Blood (2025) 146 (Supplement 1): 3920.

https://doi.org/10.1182/blood-2025-3920

Published: 2025

Journal Articles

Long-read direct RNA-seq reveals dynamic MM transcriptome made of novel isoforms and post-transcriptional modifications

Christopher Schorr, Nathan Becker, Pengyue Zhang, Attaya Suvannasankha, Travis Johnson, Kelvin Lee, Rafat Abonour, Brian Walker, Enze Liu

Blood (2025) 146 (Supplement 1): 3915.

https://doi.org/10.1182/blood-2025-3915

Published: 2025

Journal Articles

A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)

Blood (2025) 146 (Supplement 1): 4052.

https://doi.org/10.1182/blood-2025-4052

Published: 2025

Journal Articles

Single-cell DNA sequencing uncovers synergistic co-mutations in multiple myeloma

Ava Amidei, Benjamin Diamond, Elizabeth Lyubchenko, Stephanie Fernandes, Bahar Fard, Lubna Nousheen, Marc Arribas-Layton, Adam Sciambi, Dickran Kazandjian, James Hoffman, Abhishek Pandey, Marcella Kaddoura, Brian Walker, Ola Landgren, David Coffey

Blood (2025) 146 (Supplement 1): 2157.

https://doi.org/10.1182/blood-2025-2157

Published: 2025

Journal Articles

Characterization of multiple myeloma genomes with LinkPrep™ assay enables sensitive detection of somatic variation and SV-driven interactions of the 3D genome.

Nathan Becker, Enze Liu, Alexander Fortuna, Jonathon Torchia, Aneta Mikulasova, Zackary Sanborn, Lisa Munding, Brian Walker

Blood (2025) 146 (Supplement 1): 6775.

https://doi.org/10.1182/blood-2025-6775

Published: 2025

Journal Articles

A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)

Ola Landgren, Benjamin Diamond, Abhishek Pandey, James Hoffman, David Coffey, Marcella Kaddoura, Brian Walker, Rabia Bukhari, Caterine Diaz, Stephanie Mompoint, Sindy Gutierrez, Kellye Koubek, Andrew Kowalski, Leslie Gallardo, Stephanie Fernandes, Sandra Mira, Massiel Cardo Lopez, Michelle Armogan, Dickran Kazandjian

Blood (2025) 146 (Supplement 1): 5775.

https://doi.org/10.1182/blood-2025-5775

Published: 2025

Journal Articles

Applying computational modelling to a high-risk multiple myeloma data set to create novel risk stratification groupings

Orthi Shahzad, Richard Norris, Niels Weinhold, Charlotte Pawlyn, Brian Walker, Cody Ashby, Christopher Wardell, David Cairns, Martin Kaiser, Gordon Cook, Faith Davies, Mark Drayson, Roger Owen, Graham Jackson, Gareth Morgan, Simon Mitchell, John Jones

Blood (2025) 146 (Supplement 1): 5790.

https://doi.org/10.1182/blood-2025-5790

Published: 2025

Journal Articles

Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants

Blood (2025) 146 (Supplement 1): 4008.

https://doi.org/10.1182/blood-2025-4008

Published: 2025

Journal Articles

A multiomic analysis of Waldenström macroglobulinemia defines distinct disease subtypes

Blood (2025) 146 (10): 1225–1238.

https://doi.org/10.1182/blood.2024028164

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma

The molecular landscape of Waldenström macroglobulinemia identified using whole genome sequencing

Replacing FISH with a comprehensive integrated approach for tumor genotyping and immune monitoring in multiple myeloma: The flagship study

A phase 2 trial of iberdomide, carfilzomib, daratumumab and dexamethasone quadruplet therapy for relapsed/refractory multiple myeloma: The rekindle study

A phase 2 trial of abbreviated fixed-duration (Default 4 Cycles) linvoseltamab immuno-consolidation to deepen responses post newly diagnosed multiple myeloma combination therapy for minimal residual disease positivity (the IMMUNOPLANT Study)

On the cellular origins of multiple myeloma

Chromothripsis drives high-risk multiple myeloma by copy number abnormalities and rewiring the epigenome to activate oncogenic programs.

Subclonal genomic heterogeneity shapes immune crosstalk and clinical outcomes in multiple myeloma

High-dimensional profiling reveals predominant depletion of NK cell effector phenotypes in relapsed/refractory multiple myeloma patients treated with anti-CD38 therapy

Cyclin D1 beyond the cell cycle: A new role in t(11;14) multiple myeloma

Multiomic evidence of coordinated complex rearrangements, enhancer hijacking, and epigenomic signatures in the first whole-chromosome-phased myeloma genomes

Whole genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myeloma

Long-read direct RNA-seq reveals dynamic MM transcriptome made of novel isoforms and post-transcriptional modifications

A phase 2 trial of 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma (the iMMunoPET study)

Single-cell DNA sequencing uncovers synergistic co-mutations in multiple myeloma

Characterization of multiple myeloma genomes with LinkPrep™ assay enables sensitive detection of somatic variation and SV-driven interactions of the 3D genome.

A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)

Applying computational modelling to a high-risk multiple myeloma data set to create novel risk stratification groupings

Individualized treatment risk stratification using histopathology-based genomics prediction in multiple myeloma: A multicenter Study in 1429 participants

A multiomic analysis of Waldenström macroglobulinemia defines distinct disease subtypes

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only